Browse DCN

Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF13855 Leucine rich repeat
PF01462 Leucine rich repeat N-terminal domain
Function

May affect the rate of fibrils formation.

> Gene Ontology
 
Biological Process GO:0000266 mitochondrial fission
GO:0001525 angiogenesis
GO:0001655 urogenital system development
GO:0001667 ameboidal-type cell migration
GO:0001822 kidney development
GO:0001890 placenta development
GO:0001933 negative regulation of protein phosphorylation
GO:0002237 response to molecule of bacterial origin
GO:0003254 regulation of membrane depolarization
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006029 proteoglycan metabolic process
GO:0006469 negative regulation of protein kinase activity
GO:0006790 sulfur compound metabolic process
GO:0006914 autophagy
GO:0007259 JAK-STAT cascade
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007568 aging
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009612 response to mechanical stimulus
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0010594 regulation of endothelial cell migration
GO:0010596 negative regulation of endothelial cell migration
GO:0010631 epithelial cell migration
GO:0010632 regulation of epithelial cell migration
GO:0010633 negative regulation of epithelial cell migration
GO:0010821 regulation of mitochondrion organization
GO:0010822 positive regulation of mitochondrion organization
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0014706 striated muscle tissue development
GO:0016236 macroautophagy
GO:0016239 positive regulation of macroautophagy
GO:0016241 regulation of macroautophagy
GO:0016525 negative regulation of angiogenesis
GO:0018149 peptide cross-linking
GO:0018209 peptidyl-serine modification
GO:0019800 peptide cross-linking via chondroitin 4-sulfate glycosaminoglycan
GO:0022617 extracellular matrix disassembly
GO:0030166 proteoglycan biosynthetic process
GO:0030198 extracellular matrix organization
GO:0030203 glycosaminoglycan metabolic process
GO:0030204 chondroitin sulfate metabolic process
GO:0030205 dermatan sulfate metabolic process
GO:0030206 chondroitin sulfate biosynthetic process
GO:0030207 chondroitin sulfate catabolic process
GO:0030208 dermatan sulfate biosynthetic process
GO:0030336 negative regulation of cell migration
GO:0032496 response to lipopolysaccharide
GO:0032844 regulation of homeostatic process
GO:0033673 negative regulation of kinase activity
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0040013 negative regulation of locomotion
GO:0042326 negative regulation of phosphorylation
GO:0042391 regulation of membrane potential
GO:0043062 extracellular structure organization
GO:0043542 endothelial cell migration
GO:0044272 sulfur compound biosynthetic process
GO:0044273 sulfur compound catabolic process
GO:0045765 regulation of angiogenesis
GO:0046425 regulation of JAK-STAT cascade
GO:0046426 negative regulation of JAK-STAT cascade
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0048514 blood vessel morphogenesis
GO:0048608 reproductive structure development
GO:0050650 chondroitin sulfate proteoglycan biosynthetic process
GO:0050651 dermatan sulfate proteoglycan biosynthetic process
GO:0050654 chondroitin sulfate proteoglycan metabolic process
GO:0050655 dermatan sulfate proteoglycan metabolic process
GO:0051271 negative regulation of cellular component movement
GO:0051348 negative regulation of transferase activity
GO:0051881 regulation of mitochondrial membrane potential
GO:0051882 mitochondrial depolarization
GO:0051899 membrane depolarization
GO:0051900 regulation of mitochondrial depolarization
GO:0051901 positive regulation of mitochondrial depolarization
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0061458 reproductive system development
GO:0072001 renal system development
GO:0090130 tissue migration
GO:0090132 epithelium migration
GO:0090140 regulation of mitochondrial fission
GO:0090141 positive regulation of mitochondrial fission
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0097696 STAT cascade
GO:1900746 regulation of vascular endothelial growth factor signaling pathway
GO:1900747 negative regulation of vascular endothelial growth factor signaling pathway
GO:1901136 carbohydrate derivative catabolic process
GO:1901342 regulation of vasculature development
GO:1901343 negative regulation of vasculature development
GO:1901565 organonitrogen compound catabolic process
GO:1902532 negative regulation of intracellular signal transduction
GO:1902547 regulation of cellular response to vascular endothelial growth factor stimulus
GO:1902548 negative regulation of cellular response to vascular endothelial growth factor stimulus
GO:1903510 mucopolysaccharide metabolic process
GO:1904181 positive regulation of membrane depolarization
GO:1904892 regulation of STAT cascade
GO:1904893 negative regulation of STAT cascade
GO:2000021 regulation of ion homeostasis
GO:2000146 negative regulation of cell motility
GO:2000181 negative regulation of blood vessel morphogenesis
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0005518 collagen binding
GO:0005539 glycosaminoglycan binding
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0047485 protein N-terminus binding
GO:0050840 extracellular matrix binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0005589 collagen type VI trimer
GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0043202 lysosomal lumen
GO:0044420 extracellular matrix component
GO:0098644 complex of collagen trimers
GO:0098647 collagen beaded filament
> KEGG and Reactome Pathway
 
KEGG hsa04350 TGF-beta signaling pathway
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-2024101: CS/DS degradation
R-HSA-2022870: Chondroitin sulfate biosynthesis
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3595174: Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595172: Defective CHST3 causes SEDCJD
R-HSA-3595177: Defective CHSY1 causes TPBS
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-2022923: Dermatan sulfate biosynthesis
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-3000178: ECM proteoglycans
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DCN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between DCN and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22087031Lung CarcinomaInhibit immunityFirst, decorin acted as an endogenous ligand of Toll-like receptors 2 and 4 and stimulated production of proinflammatory molecules, including PDCD4, in macrophages. Second, decorin prevented translational repression of PDCD4 by decreasing the activity of transforming growth factor-β1 and the abundance of oncogenic miR-21, a translational inhibitor of PDCD4. Moreover, increased PDCD4 abundance led to decreased release of the anti-inflammatory cytokine interleukin-10, thereby making the cytokine profile more proinflammatory.
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DCN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3910.0344
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.6380.422
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4560.827
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2660.72
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.790.769
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3930.906
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1210.891
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3770.867
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.380.89
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.8420.524
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 284.8680.204
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3140.17
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DCN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DCN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DCN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DCN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DCN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DCN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DCN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDCN
Namedecorin
Aliases DSPG2; SLRR1B; decorin proteoglycan; CSCD; PG40; PG-S2; bone proteoglycan II; dermatan sulphate proteoglycan ......
Chromosomal Location12q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DCN collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting DCN.
ID Name Drug Type Targets #Targets
DB03754TromethamineSmall MoleculeAMD1, CANT1, DCN, NEIL1, VEGFA5